ALGS vs. ASMB, RANI, VXRT, ME, ABOS, AMLX, TELO, ADVM, IPSC, and ADAG
Should you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Assembly Biosciences (ASMB), Rani Therapeutics (RANI), Vaxart (VXRT), 23andMe (ME), Acumen Pharmaceuticals (ABOS), Amylyx Pharmaceuticals (AMLX), Telomir Pharmaceuticals (TELO), Adverum Biotechnologies (ADVM), Century Therapeutics (IPSC), and Adagene (ADAG). These companies are all part of the "medical" sector.
Assembly Biosciences (NASDAQ:ASMB) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.
Aligos Therapeutics has a consensus target price of $75.00, indicating a potential upside of 499.52%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aligos Therapeutics is more favorable than Assembly Biosciences.
Assembly Biosciences received 218 more outperform votes than Aligos Therapeutics when rated by MarketBeat users. However, 63.16% of users gave Aligos Therapeutics an outperform vote while only 59.02% of users gave Assembly Biosciences an outperform vote.
Assembly Biosciences has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,100.48%. Aligos Therapeutics' return on equity of -110.59% beat Assembly Biosciences' return on equity.
In the previous week, Assembly Biosciences had 6 more articles in the media than Aligos Therapeutics. MarketBeat recorded 7 mentions for Assembly Biosciences and 1 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 1.05 beat Assembly Biosciences' score of 0.05 indicating that Aligos Therapeutics is being referred to more favorably in the news media.
Assembly Biosciences has higher revenue and earnings than Aligos Therapeutics.
19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 5.1% of Assembly Biosciences shares are held by company insiders. Comparatively, 16.5% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Assembly Biosciences has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500.
Summary
Aligos Therapeutics beats Assembly Biosciences on 10 of the 16 factors compared between the two stocks.
Get Aligos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aligos Therapeutics Competitors List
Related Companies and Tools
